DVHGF (Devonian Health Group) Total Long-Term Assets: $5.12 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DVHGF Devonian Health Group Inc DVHGF
59 GF Score
Price $7.00
GF Value $2.00
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Devonian Health Group Total Long-Term Assets?

Devonian Health Group DVHGF 59 Total Long-Term Assets is $5.12 Mil as of Apr. 2026. GuruFocus rates DVHGF with a GF Score™ of 59/100 and a GF Value™ of $2.00 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Devonian Health Group's Total Long-Term Assets for the quarter that ended in Apr. 2026 was $5.12 Mil.

Devonian Health Group Total Long-Term Assets Related Terms

Devonian Health Group Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Devonian Health Group's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devonian Health Group Total Long-Term Assets Chart

Devonian Health Group Annual Data
Trend Jun16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.13 10.18 9.71 8.95 5.19

Devonian Health Group Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.14 5.19 5.05 5.15 5.12
DVHGF
59GF Score
Devonian Health Group Inc DVHGF
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Devonian Health Group Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $5.12 Mil mean?
Devonian Health Group (DVHGF) has a Total Long-Term Assets of $5.12 Mil as of Apr. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Devonian Health Group and its competitors.
Is Devonian Health Group's Total Long-Term Assets too high?
Devonian Health Group's current Total Long-Term Assets is $5.12 Mil. Overall, Devonian Health Group has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Total Long-Term Assets compare to VRTX and REGN?
Devonian Health Group's Total Long-Term Assets of $5.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current Total Long-Term Assets is $5.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.00, compared to a current price of $7.00 — trading 250% above its estimated fair value. The current Total Long-Term Assets is $5.12 Mil. Devonian Health Group's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Total Long-Term Assets is $5.12 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Devonian Health Group (DVHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued. The current stock price of $7.00 is trading 250% above its estimated GF Value™ of $2.00. GuruFocus considers Devonian Health Group to be Significantly Overvalued.

Key valuation signals for DVHGF:

  • Total Long-Term Assets: $5.12 Mil
  • GF Value™: $2.00 vs. price of $7.00 (250% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Devonian Health Group Business Description

Other Exchanges GSD:Canada
Address 360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
59GF Score

Get the complete analysis for DVHGF

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$2.00
GF Value